Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Aandeel Pharming Group AEX:PHARM.NL, NL0010391025

  • 0,745 24 jun 2022 17:36
  • +0,022 (+2,97%) Dagrange 0,728 - 0,754
  • 2.734.765 Gem. (3M) 2,8M

Pharming koopt commerciële rechten Ruconest terug

9 Posts
| Omlaag ↓
  1. Berdientje 30 december 2019 08:18
    • Pharming will take control of commercial rights to its product RUCONEST® in all 36 remaining countries
    • Pharming will pay a total of €7.5 million in two tranches for a smooth transition of the existing activity and to terminate the license early
    • The transaction will be accretive to earnings immediately
    Leiden, the Netherlands – 30 December 2019


    Pharming Group N.V. (Euronext Amsterdam: PHARM) today announced it has entered into a definitive agreement with Swedish Orphan Biovitrum AB (publ) (“Sobi”) to reacquire the commercial rights to Pharming’s product, RUCONEST®, in all remaining territories, which includes all remaining EU markets. Under the agreement, the license is being terminated with effect from 1 January 2020 in all 36 countries with a smooth handover planned in the countries where Sobi has sales activities. Pharming will pay Sobi €7.5 million in two tranches.
    Following the strategic decision to reaquire the North American commercial rights for RUCONEST® in December 2016 from its licensee Valeant Pharmaceuticals International (now “Bausch Health”), Pharming has increased US sales significantly. It is anticipated that, while not of the same commercial scale as the US, a growth increase in the additional 36 territories can be expected. The transaction will be accretive to earnings immediately.
    RUCONEST® has been licensed for a total of 60 different countries in this region since 2010, and was launched in a number of these countries. Commercialization rights for RUCONEST® in 24 of the 60 countries have been returned to Pharming in previous years.
    In order to ensure that existing RUCONEST® patients can continue to receive their therapy, Pharming will be cooperating with Sobi to replace all contracts for distribution and other services as quickly as possible, and to transfer existing reimbursement approvals where possible. While Pharming will be responsible for the distribution of RUCONEST® in the 36 reaquired territories from the 1 January 2020, it may be some time before all activities and full control have been transferred. No personnel will be transferring between the two companies.
  2. Berdientje 30 december 2019 08:19
    Sijmen de Vries, Chief Executive of Pharming, said:

    "Our strategic decision to reacquire the commercial rights to RUCONEST® from SOBI builds on the commercial success of the product in the US and now means we own commerical rights to our lead asset for the treatment of HAE in all countries, except some markets in Latin America, Israel and South Korea. The transaction will enable us to drive further growth of RUCONEST® and will be accretive to earnings immediately. In addition, we will expand our existing commercial infrastructure in Europe to support the expected launch of future new products from our pipeline, including the recently in-licensed, late-stage compound, leniolisib, for the treatment of APDS."
    Under the terms of the agreement, Pharming will pay a total payment of €7.5 million in two tranches, the larger part upfront with a final payment once all transition activities are complete or underway. There are no further future payments under this agreement
  3. Berdientje 30 december 2019 08:20
    RUCONEST® is also being examined for approval for the treatment of HAE in young children (2-13 years of age) and evaluated for various additional follow-on indications.

    Pharming’s technology platform includes a unique, GMP-compliant, validated process for the production of pure recombinant human proteins that has proven capable of producing industrial quantities of high quality recombinant human proteins in a more economical and less immunogenetic way compared with current cell-line based methods. Leads for enzyme replacement therapy (“ERT”) for Pompe and Fabry’s diseases are being optimized at present, with additional programs not involving ERT also being explored at an early stage at present.
    Pharming has a long-term partnership with the China State Institute of Pharmaceutical Industry (“CSIPI”), a Sinopharm company, for joint global development of new products, starting with recombinant human Factor VIII for the treatment of Haemophilia A. Pre-clinical development and manufacturing will take place to global standards at CSIPI and are funded by CSIPI. Clinical development will be shared between the partners with each partner taking the costs for their territories under the partnership.
  4. Berdientje 30 december 2019 08:28
    LEIDEN (AFN) - Pharming neemt alle aan het Zweedse Orphan Biovitrum (Sobi) gelicentieerde markten voor zijn medicijn Ruconest terug. De biotechnoloog betaalt daarvoor 7,5 miljoen euro in twee tranches. De transactie draagt direct bij aan de winstgevendheid.

    De licentie met Sobi wordt per 1 januari stopgezet in alle betreffende 36 landen, waaronder de resterende EU-markten. Ruconest was in deze regio sinds 2010 gelicentieerd voor in totaal 60 verschillende landen en werd in een aantal daarvan voor het eerst op de markt gebracht. De commerciële rechten van 24 van de 60 landen werden in voorgaande jaren aan Pharming teruggegeven.

    In december 2016 kocht Pharming al de commerciële rechten in Noord-Amerika terug van licentiehouder Valeant Pharmaceuticals. Sindsdien wist Pharming de Amerikaanse omzet aanzienlijk te verhogen. Hoewel niet van dezelfde omvang als in de VS, mag een omzetgroei in de additionele 36 landen worden verwacht.

    Pharming heeft nu de commerciële rechten op zijn product voor de behandeling van erfelijk angio-oedeem in alle landen, behalve een aantal in Latijns-Amerika en in Israël en Zuid-Korea.
  5. EK-sight-ing-trader 30 december 2019 10:01
    pharming doet een goede stap 36 landen waar ze mogen gaan verkopen, maw meer inkomsten in de nabije toekomst ... en het aandeel maakt een heel klein vreugde sprongetje.... om vervolgens weer snel terug te dalen naar waar het vandaan kwam.....

    eeuuuhh hallo ?????

    what the F is going on....?????
  6. BORISNEDU 30 december 2019 10:39
    quote:

    EK-sight-ing-trader schreef op 30 december 2019 10:01:

    pharming doet een goede stap 36 landen waar ze mogen gaan verkopen, maw meer inkomsten in de nabije toekomst ... en het aandeel maakt een heel klein vreugde sprongetje.... om vervolgens weer snel terug te dalen naar waar het vandaan kwam.....

    eeuuuhh hallo ?????

    what the F is going on....?????
    Omdat het kan
9 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Pharming Group Meer »

Koers 0,745   Verschil +0,02 (+2,97%)
Laag 0,728   Volume 2.734.765
Hoog 0,754   Gem. Volume 2.786.732
24 jun 2022 17:36
Premium

Spanning stijgt rond Pharming

Het laatste advies leest u als IEX Premium-lid

Inloggen Ontdek Premium

Gerelateerde Video's

  1. video thumbnail

    Outlook Pharming

    7 juni 2018 16:58 - Vimeo

  2. video thumbnail

    Pharming: Groeiperspectieven

    13 maart 2018 22:16 - Vimeo

  3. video thumbnail

    Pharming kan verder omhoog

    27 oktober 2017 17:23 - Vimeo

  4. video thumbnail

    Arend Jan Kamp over Pharming

    26 oktober 2017 13:24 - Vimeo

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links